Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state

Translational Research

Volumn 179, Issue , 2017, Pages 155-167

  Djuric, Zora ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYTOKINE; FATTY ACID; FLAGELLIN; ICOSANOID; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MUCIN;

ANTIGEN FUNCTION; CANCER RISK; DIET; DIETARY INTAKE; ENERGY BALANCE; FAT INTAKE; FOOD COMPOSITION; HIGH ENERGY DIET; HOST CELL; HUMAN; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE FLORA; LIPID DIET; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; COMPLICATION; NEOPLASMS; RISK FACTOR;

ANIMALS; DIET; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 84995957206     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.07.017     Document Type: Review

References (216)

1. 1 World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. 2007, American Institute for Cancer Research, Washington, DC.
2. 2 Wang, J., Yang, D.L., Chen, Z.Z., Gou, B.F., Associations of body mass index with cancer incidence among populations, genders, and menopausal status: A systematic review and meta-analysis. Cancer Epidemiol 42 (2016), 1–8.
3. 3 Anderson, A.S., Key, T.J., Norat, T., et al. European Code against Cancer 4th Edition: Obesity, body fatness and cancer. Cancer Epidemiol 39 Suppl 1 (2015), S34–S45.
4. 4 Ning, Y., Wang, L., Giovannucci, E.L., A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 11 (2010), 19–30.
5. 5 Okabayashi, K., Ashrafian, H., Hasegawa, H., et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastroenterol 107 (2012), 1175–1185.
6. 6 Byers, T., Sedjo, R.L., Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer 22 (2015), R125–R134.
7. 7 Lin, W.W., Karin, M., A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007), 1175–1183.
8. 8 Lumeng, C.N., Saltiel, A.R., Inflammatory links between obesity and metabolic disease. J Clin Invest 121 (2011), 2111–2117.
9. 9 Fenton, J.I., Nunez, N.P., Yakar, S., et al. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes Metab 11 (2009), 343–354.
10. 10 Strissel, K.J., DeFuria, J., Shaul, M.E., et al. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring) 18 (2010), 1918–1925.
11. 11 Shoelson, S.E., Herrero, L., Naaz, A., Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007), 2169–2180.
12. 12 Ferrante, A.W. Jr., Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262 (2007), 408–414.
13. 13 Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117 (2007), 175–184.
14. 14 Jain, S., Gautam, V., Naseem, S., Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci 3 (2011), 118–127.
15. 15 Volanakis, J.E., Complement activation by C-reactive protein complexes. Ann N Y Acad Sci 389 (1982), 235–250.
16. 16 Chan, D.S., Bandera, E.V., Greenwood, D.C., Norat, T., Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev 24 (2015), 1439–1449.
17. 17 Tsilidis, K.K., Branchini, C., Guallar, E., et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123 (2008), 1133–1140.
18. 18 Zhou, B., Shu, B., Yang, J., et al. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control 25 (2014), 1397–1405.
19. 19 Gunter, M.J., Wang, T., Cushman, M., et al. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst, 107, 2015 pii: djv169.
20. 20 Nimptsch, K., Aleksandrova, K., Boeing, H., et al. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. Int J Cancer 136 (2015), 1181–1192.
21. 21 Pierce, B.L., Ballard-Barbash, R., Bernstein, L., et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27 (2009), 3437–3444.
22. 22 Allin, K.H., Bojesen, S.E., Nordestgaard, B.G., Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27 (2009), 2217–2224.
23. 23 Han, Y., Mao, F., Wu, Y., et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers 26 (2011), 209–215.
24. 24 Liu, S., Ginestier, C., Ou, S.J., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71 (2011), 614–624.
25. 25 Allin, K.H., Nordestgaard, B.G., Flyger, H., Bojesen, S.E., Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res, 13, 2011, R55.
26. 26 Soria, G., Ofri-Shahak, M., Haas, I., et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 11, 2011, 130.
27. 27 Sicking, I., Edlund, K., Wesbuer, E., et al. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One, 9, 2014, e111306.
28. 28 Villasenor, A., Flatt, S.W., Marinac, C., et al. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev 23 (2014), 189–199.
29. 29 Alkhateeb, A.A., Leitzel, K., Ali, S.M., et al. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One, 7, 2012, e51379.
30. 30 Jin, W.J., Xu, J.M., Xu, W.L., Gu, D.H., Li, P.W., Diagnostic value of interleukin-8 in colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol 20 (2014), 16334–16342.
31. 31 Joshi, R.K., Lee, S.A., Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev 15 (2014), 397–405.
32. 32 Feitoza, C.Q., Semedo, P., Goncalves, G.M., et al. Modulation of inflammatory response by selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 in acute kidney injury. Inflamm Res 59 (2010), 167–175.
33. 33 Reader, J., Holt, D., Fulton, A., Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30 (2011), 449–463.
34. 34 Rundhaug, J.E., Simper, M.S., Surh, I., Fischer, S.M., The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 30 (2011), 465–480.
35. 35 Wang, D., Dubois, R.N., The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29 (2010), 781–788.
36. 36 Harvey, A.E., Lashinger, L.M., Hursting, S.D., The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229 (2011), 45–52.
37. 37 Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat Rev Cancer 10 (2010), 181–193.
38. 38 Chen, E.P., Smyth, E.M., COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat 96 (2011), 14–20.
39. 39 Wang, X., Docanto, M.M., Sasano, H., et al. Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mechanism for the regulation of aromatase in obesity and breast cancer. Cancer Res 75 (2015), 645–655.
40. 40 Li, S., Xu, X., Jiang, M., et al. Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. Mol Med Rep 11 (2015), 4454–4462.
41. 41 Vona-Davis, L., Rose, D.P., The obesity-inflammation-eicosanoid axis in breast cancer. J Mammary Gland Biol Neoplasia 18 (2013), 291–307.
42. 42 Cui, Y., Shu, X.O., Gao, Y.T., et al. Urinary prostaglandin E2 metabolite and breast cancer risk. Cancer Epidemiol Biomarkers Prev 23 (2014), 2866–2873.
43. 43 Kim, S., Taylor, J.A., Milne, G.L., Sandler, D.P., Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila) 6 (2013), 511–518.
44. 44 Morris, P.G., Zhou, X.K., Milne, G.L., et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) 6 (2013), 428–436.
45. 45 Wang, D., DuBois, R.N., Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) 6 (2013), 507–510.
46. 46 Bowers, L.W., Maximo, I.X., Brenner, A.J., et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res 74 (2014), 4446–4457.
47. 47 Yehuda-Shnaidman, E., Schwartz, B., Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes Rev 13 (2012), 1083–1095.
48. 48 Grivennikov, S.I., Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35 (2013), 229–244.
49. 49 Vendramini-Costa, D.B., Carvalho, J.E., Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18 (2012), 3831–3852.
50. 50 Duffin, R., O'Connor, R.A., Crittenden, S., et al. Prostaglandin E(2) constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science 351 (2016), 1333–1338.
51. 51 Montrose, D.C., Nakanishi, M., Murphy, R.C., et al. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat 116-117 (2015), 26–36.
52. 52 Sonoshita, M., Takaku, K., Oshima, M., Sugihara, K., Taketo, M.M., Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62 (2002), 6846–6849.
53. 53 Takeda, H., Sonoshita, M., Oshima, H., et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 63 (2003), 4872–4877.
54. 54 Kargman, S.L., O'Neil, G.P., Vickers, P.J., et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55 (1995), 2556–2559.
55. 55 Eberhart, C.E., Coffey, R.J., Radhika, A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994), 1183–01188.
56. 56 Sano, H., Kawahito, Y., Wilder, R.L., Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55 (1995), 3785–3789.
57. 57 Martinez, M.E., Heddens, D., Earnest, D.L., et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst 91 (1999), 950–953.
58. 58 Delage, B., Rullier, A., Capdepont, M., Rullier, E., Cassand, P., The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J, 6, 2007, 20.
59. 59 Lee, S.H., Han, K., Yang, H.K., et al. A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. Nutr Diabetes, 5, 2015, e149.
60. 60 Gomez-Ambrosi, J., Catalan, V., Rodriguez, A., et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care 37 (2014), 2813–2821.
61. 61 Varady, K.A., Tussing, L., Bhutani, S., Braunschweig, C.L., Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 58 (2009), 1096–1101.
62. 62 Klempel, M.C., Varady, K.A., Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev 69 (2011), 145–154.
63. 63 Madsen, E.L., Rissanen, A., Bruun, J.M., et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 158 (2008), 179–187.
64. 64 Pendyala, S., Neff, L.M., Suarez-Farinas, M., Holt, P.R., Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 93 (2011), 234–242.
65. 65 Selvin, E., Paynter, N.P., Erlinger, T.P., The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 167 (2007), 31–39.
66. 66 Hermsdorff, H.H., Zulet, M.A., Abete, I., Martinez, J.A., Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine 36 (2009), 445–451.
67. 67 Olivo-Marston, S.E., Hursting, S.D., Perkins, S.N., et al. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microrna expression. PLoS One, 9, 2014, e94765.
68. 68 Ley, R.E., Backhed, F., Turnbaugh, P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075.
69. 69 Nadal, I., Santacruz, A., Marcos, A., et al. Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) 33 (2009), 758–767.
70. 70 Santacruz, A., Marcos, A., Warnberg, J., et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 17 (2009), 1906–1915.
71. 71 Furet, J.P., Kong, L.C., Tap, J., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59 (2010), 3049–3057.
72. 72 Ravussin, E., Redman, L.M., Adiposity and comorbidities: favorable impact of caloric restriction. Nestle Nutr Workshop Ser Pediatr Program 63 (2009), 135–147.
73. 73 Fleissner, C.K., Huebel, N., Abd El-Bary, M.M., et al. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 104 (2010), 919–929.
74. 74 Arumugam, M., Raes, J., Pelletier, E., et al. Enterotypes of the human gut microbiome. Nature 473 (2011), 174–180.
75. 75 Jumpertz, R., Le, D.S., Turnbaugh, P.J., et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 94 (2011), 58–65.
76. 76 Zhang, H., DiBaise, J.K., Zuccolo, A., et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106 (2009), 2365–2370.
77. 77 Momozawa, Y., Deffontaine, V., Louis, E., Medrano, J.F., Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. PLoS One, 6, 2011, e16952.
78. 78 Mozes, S., Bujnakova, D., Sefcikova, Z., Kmet, V., Intestinal microflora and obesity in rats. Folia Microbiol (Praha) 53 (2008), 225–228.
79. 79 Murphy, E.F., Cotter, P.D., Healy, S., et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59 (2010), 1635–1642.
80. 80 Faith, J.J., Guruge, J.L., Charbonneau, M., et al. The long-term stability of the human gut microbiota. Science, 341, 2013, 1237439.
81. 81 Walker, A.W., Parkhill, J., Microbiology. Fighting obesity with bacteria. Science 341 (2013), 1069–1070.
82. 82 Hamilton, M.K., Boudry, G., Lemay, D.G., Raybould, H.E., Changes in intestinal barrier function and gut microbiota in high-fat diet fed rats are dynamic and region dependent. Am J Physiol Gastrointest Liver Physiol 308 (2015), G840–G851.
83. 83 Blaut, M., Gut microbiota and energy balance: role in obesity. Proc Nutr Soc 74 (2015), 227–234.
84. 84 Salyers, A.A., Palmer, J.K., Wilkins, T.D., Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr 31 (1978), S128–S130.
85. 85 Martens, E.C., Lowe, E.C., Chiang, H., et al. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol, 9, 2011, e1001221.
86. 86 Finucane, M.M., Sharpton, T.J., Laurent, T.J., Pollard, K.S., A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PLoS One, 9, 2014, e84689.
87. 87 Louis, S., Tappu, R.M., Damms-Machado, A., Huson, D.H., Bischoff, S.C., Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. PLoS One, 11, 2016, e0149564.
88. 88 Knoch, B., Barnett, M.P., McNabb, W.C., et al. Dietary arachidonic acid-mediated effects on colon inflammation using transcriptome analysis. Mol Nutr Food Res 54 Suppl 1 (2010), S62–S74.
89. 89 Greiner, T., Backhed, F., Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 22 (2011), 117–123.
90. 90 Lambris, J.D., Ricklin, D., Geisbrecht, B.V., Complement evasion by human pathogens. Nat Rev Microbiol 6 (2008), 132–142.
91. 91 Birkinshaw, R.W., Kjer-Nielsen, L., Eckle, S.B., McCluskey, J., Rossjohn, J., MAITs, MR1 and vitamin B metabolites. Curr Opin Immunol 26 (2014), 7–13.
92. 92 Abe, R., Oda, S., Sadahiro, T., et al. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit Care, 14, 2010, R27.
93. 93 Amar, J., Burcelin, R., Ruidavets, J.B., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 87 (2008), 1219–1223.
94. 94 Cani, P.D., Delzenne, N.M., The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15 (2009), 1546–1558.
95. 95 Laugerette, F., Vors, C., Peretti, N., Michalski, M.C., Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 93 (2011), 39–45.
96. 96 Lajunen, T., Vikatmaa, P., Bloigu, A., et al. Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index in patients with cardiovascular disease. Innate Immun 14 (2008), 375–382.
97. 97 Lassenius, M.I., Pietilainen, K.H., Kaartinen, K., et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34 (2011), 1809–1815.
98. 98 Uematsu, S., Matsumoto, M., Takeda, K., Akira, S., Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168 (2002), 5811–5816.
99. 99 Blatteis, C.M., Li, S., Li, Z., Feleder, C., Perlik, V., Cytokines, PGE2 and endotoxic fever: a re-assessment. Prostaglandins Other Lipid Mediat 76 (2005), 1–18.
100. 100 Killeen, S.D., Wang, J.H., Andrews, E.J., Redmond, H.P., Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 100 (2009), 1589–1602.
101. 101 Xiao, S., Fei, N., Pang, X., et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 87 (2014), 357–367.
102. 102 Kobayashi, M., Saitoh, S., Tanimura, N., et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 176 (2006), 6211–6218.
103. 103 Godowski, P.J., A smooth operator for LPS responses. Nat Immunol 6 (2005), 544–546.
104. 104 Cani, P.D., Amar, J., Iglesias, M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
105. 105 Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., et al. Loss of function mutation in toll-like receptor-4 does not offer protection against obesity and insulin resistance induced by a diet high in trans fat in mice. J Inflamm (Lond), 8, 2011, 2.
106. 106 Reigstad, C.S., Lunden, G.O., Felin, J., Backhed, F., Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One, 4, 2009, e5842.
107. 107 Carothers, A.M., Davids, J.S., Damas, B.C., Bertagnolli, M.M., Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res 70 (2010), 4433–4442.
108. 108 Liu, L., Li, Y.H., Niu, Y.B., et al. An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-kappaB pathway in a mouse model of colitis-associated colon cancer. Carcinogenesis 31 (2010), 1822–1832.
109. 109 Murillo, G., Nagpal, V., Tiwari, N., Benya, R.V., Mehta, R.G., Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J Steroid Biochem Mol Biol 121 (2010), 403–407.
110. 110 Rakoff-Nahoum, S., Medzhitov, R., Toll-like receptors and cancer. Nat Rev Cancer 9 (2009), 57–63.
111. 111 Sitaraman, S.V., Klapproth, J.M., Moore, D.A. 3rd, et al. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 288 (2005), G403–G406.
112. 112 Hayashi, F., Smith, K.D., Ozinsky, A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001), 1099–1103.
113. 113 Steiner, T.S., How flagellin and toll-like receptor 5 contribute to enteric infection. Infect Immun 75 (2007), 545–552.
114. 114 Wong, J.M., de Souza, R., Kendall, C.W., Emam, A., Jenkins, D.J., Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40 (2006), 235–243.
115. 115 Soerensen, K.V., Thorning, T.K., Astrup, A., Kristensen, M., Lorenzen, J.K., Effect of dairy calcium from cheese and milk on fecal fat excretion, blood lipids, and appetite in young men. Am J Clin Nutr 99 (2014), 984–991.
116. 116 Ijiri, D., Nojima, T., Kawaguchi, M., et al. Effects of feeding outer bran fraction of rice on lipid accumulation and fecal excretion in rats. Biosci Biotechnol Biochem 79 (2015), 1337–1341.
117. 117 Rossi, L., Kadamba, P., Hugosson, C., et al. Pediatric short bowel syndrome: adaptation after massive small bowel resection. J Pediatr Gastroenterol Nutr 45 (2007), 213–221.
118. 118 Snipes, R.L., Limited fat absorption in the large intestine of mice. A morphological study. Acta Anat (Basel) 99 (1977), 435–439.
119. 119 Erridge, C., Attina, T., Spickett, C.M., Webb, D.J., A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86 (2007), 1286–1292.
120. 120 Moreira, A.P., Texeira, T.F., Ferreira, A.B., Peluzio Mdo, C., Alfenas Rde, C., Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108 (2012), 801–809.
121. 121 Everard, A., Lazarevic, V., Gaia, N., et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 8 (2014), 2116–2130.
122. 122 Nicholson, J.K., Holmes, E., Kinross, J., et al. Host-gut microbiota metabolic interactions. Science 336 (2012), 1262–1267.
123. 123 Deopurkar, R., Ghanim, H., Friedman, J., et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 33 (2010), 991–997.
124. 124 Ghanim, H., Abuaysheh, S., Sia, C.L., et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 32 (2009), 2281–2287.
125. 125 Morselli, E., Frank, A.P., Palmer, B.F., et al. A sexually dimorphic hypothalamic response to chronic high-fat diet consumption. Int J Obes (Lond) 40 (2016), 206–209.
126. 126 Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med, 1, 2009, 6ra14.
127. 127 De Bandt, J.P., Waligora-Dupriet, A.J., Butel, M.J., Intestinal microbiota in inflammation and insulin resistance: relevance to humans. Curr Opin Clin Nutr Metab Care 14 (2011), 334–340.
128. 128 Lam, Y.Y., Ha, C.W., Hoffmann, J.M., et al. Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice. Obesity (Silver Spring) 23 (2015), 1429–1439.
129. 129 Ghosh, S., DeCoffe, D., Brown, K., et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One, 8, 2013, e55468.
130. 130 de Lima-Salgado, T.M., Alba-Loureiro, T.C., do Nascimento, C.S., Nunes, M.T., Curi, R., Molecular mechanisms by which saturated fatty acids modulate TNF-alpha expression in mouse macrophage lineage. Cell Biochem Biophys 59 (2011), 89–97.
131. 131 Walton, K.L., Holt, L., Sartor, R.B., Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 296 (2009), G601–G611.
132. 132 Plummer, S.M., Hill, K.A., Festing, M.F., et al. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 10 (2001), 1295–1299.
133. 133 Abnous, K., Brooks, S.P., Kwan, J., et al. Diets enriched in oat bran or wheat bran temporally and differentially alter the composition of the fecal community of rats. J Nutr 139 (2009), 2024–2031.
134. 134 Hamer, H.M., Jonkers, D.M., Bast, A., et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28 (2009), 88–93.
135. 135 Peng, L., Li, Z.R., Green, R.S., Holzman, I.R., Lin, J., Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139 (2009), 1619–1625.
136. 136 Suzuki, T., Yoshida, S., Hara, H., Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 100 (2008), 297–305.
137. 137 Matarrese, P., Petitta, C., Scirocco, A., et al. Antioxidants counteract lipopolysaccharide-triggered alterations of human colonic smooth muscle cells. Free Radic Biol Med 53 (2012), 2102–2111.
138. 138 Pauwels, E.K., The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk. Med Princ Pract 20 (2011), 103–111.
139. 139 Romaguera, D., Norat, T., Vergnaud, A.C., et al. Mediterranean dietary patterns and prospective weight change in participants of the EPIC-PANACEA project. Am J Clin Nutr 92 (2010), 912–921.
140. 140 Esposito, K., Kastorini, C.M., Panagiotakos, D.B., Giugliano, D., Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metab Syndr Relat Disord 9 (2011), 1–12.
141. 141 Sidahmed, E., Cornellier, M.L., Ren, J., et al. Development of exchange lists for Mediterranean and Healthy Eating diets: implementation in an intervention trial. J Hum Nutr Diet 27 (2014), 413–425.
142. 142 Hu, S., Wang, Y., Lichtenstein, L., et al. Regional differences in colonic mucosa-associated microbiota determine the physiological expression of host heat shock proteins. Am J Physiol Gastrointest Liver Physiol 299 (2010), G1266–G1275.
143. 143 Booijink, C.C., El-Aidy, S., Rajilic-Stojanovic, M., et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol 12 (2010), 3213–3227.
144. 144 Derrien, M., Vaughan, E.E., Plugge, C.M., de Vos, W.M., Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54 (2004), 1469–1476.
145. 145 De Lisle, R.C., Roach, E., Jansson, K., Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 293 (2007), G577–G584.
146. 146 Gosiewski, T., Strus, M., Fyderek, K., et al. Horizontal distribution of the fecal microbiota in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 54 (2012), 20–27.
147. 147 Sonnenburg, J.L., Xu, J., Leip, D.D., et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307 (2005), 1955–1959.
148. 148 Koropatkin, N.M., Cameron, E.A., Martens, E.C., How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 10 (2012), 323–335.
149. 149 Marcobal, A., Barboza, M., Sonnenburg, E.D., et al. Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe 10 (2011), 507–514.
150. 150 Pudlo, N.A., Urs, K., Kumar, S.S., et al. Symbiotic human gut bacteria with variable metabolic priorities for host mucosal glycans. MBio 6 (2015), e01282–e01315.
151. 151 Yasuda, K., Oh, K., Ren, B., et al. Biogeography of the intestinal mucosal and lumenal microbiome in the rhesus macaque. Cell Host Microbe 17 (2015), 385–391.
152. 152 Albenberg, L., Esipova, T.V., Judge, C.P., et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 147 (2014), 1055–1063.e8.
153. 153 Boland, C.R., Montgomery, C.K., Kim, Y.S., A cancer-associated mucin alteration in benign colonic polyps. Gastroenterology 82 (1982), 664–672.
154. 154 Grivennikov, S.I., Karin, M., Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70 Suppl 1 (2011), i104–i108.
155. 155 Smirnova, M.G., Guo, L., Birchall, J.P., Pearson, J.P., LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol 221 (2003), 42–49.
156. 156 Plaisancie, P., Ducroc, R., El Homsi, M., et al. Luminal leptin activates mucin-secreting goblet cells in the large bowel. Am J Physiol Gastrointest Liver Physiol 290 (2006), G805–G812.
157. 157 Smirnova, M.G., Kiselev, S.L., Birchall, J.P., Pearson, J.P., Up-regulation of mucin secretion in HT29-MTX cells by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-6. Eur Cytokine Netw 12 (2001), 119–125.
158. 158 El Homsi, M., Ducroc, R., Claustre, J., et al. Leptin modulates the expression of secreted and membrane-associated mucins in colonic epithelial cells by targeting PKC, PI3K, and MAPK pathways. Am J Physiol Gastrointest Liver Physiol 293 (2007), G365–G373.
159. 159 Jarry, A., Vallette, G., Branka, J.E., Laboisse, C., Direct secretory effect of interleukin-1 via type I receptors in human colonic mucous epithelial cells (HT29-C1.16E). Gut 38 (1996), 240–242.
160. 160 Enss, M.L., Cornberg, M., Wagner, S., et al. Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 49 (2000), 162–169.
161. 161 Krimi, R.B., Kotelevets, L., Dubuquoy, L., et al. Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm Bowel Dis 14 (2008), 931–941.
162. 162 Rescigno, M., The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol 32 (2011), 256–264.
163. 163 Gustafsson, J.K., Navabi, N., Rodriguez-Pineiro, A.M., et al. Dynamic changes in mucus thickness and ion secretion during Citrobacter rodentium infection and clearance. PLoS One, 8, 2013, e84430.
164. 164 Macfarlane, S., Woodmansey, E.J., Macfarlane, G.T., Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system. Appl Environ Microbiol 71 (2005), 7483–7492.
165. 165 Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137 (2009), 1716–1724.e1–2.
166. 166 Steppan, C.M., Brown, E.J., Wright, C.M., et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 98 (2001), 502–506.
167. 167 Yamauchi, J., Kawai, Y., Yamada, M., et al. Altered expression of goblet cell- and mucin glycosylation-related genes in the intestinal epithelium during infection with the nematode Nippostrongylus brasiliensis in rat. APMIS 114 (2006), 270–278.
168. 168 Asano, T., Sakosda, H., Fujishiro, M., et al. Physiological significance of resistin and resistin-like molecules in the inflammatory process and insulin resistance. Curr Diabetes Rev 2 (2006), 449–454.
169. 169 Barnes, S.L., Vidrich, A., Wang, M.L., et al. Resistin-like molecule beta (RELM beta/FIZZ2) is highly expressed in the ileum of SAMP1/YitFc mice and is associated with initiation of ileitis. J Immunol 179 (2007), 7012–7020.
170. 170 Hogan, S.P., Seidu, L., Blanchard, C., et al. Resistin-like molecule beta regulates innate colonic function: Barrier integrity and inflammation susceptibility. J Allergy Clin Immunol 118 (2006), 257–268.
171. 171 Renigunta, A., Hild, C., Rose, F., et al. Human RELM beta is a mitogenic factor in lung cells and induced in hypoxia. FEBS Lett 580 (2006), 900–903.
172. 172 Endo, H., Hosono, K., Fujisawa, T., et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut 58 (2009), 1637–1643.
173. 173 Everard, A., Belzer, C., Geurts, L., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110 (2013), 9066–9071.
174. 174 Underwood, M.A., Intestinal dysbiosis: Novel mechanisms by which gut microbes trigger and prevent disease. Prev Med 65C (2014), 133–137.
175. 175 Shin, N.R., Lee, J.C., Lee, H.Y., et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63 (2014), 727–735.
176. 176 Cohen, J., The detection and interpretation of endotoxaemia. Intensive Care Med 26 Suppl 1 (2000), S51–S56.
177. 177 Novitsky, T.J., Limitations of the Limulus amebocyte lysate test in demonstrating circulating lipopolysaccharides. Ann N Y Acad Sci 851 (1998), 416–421.
178. 178 Moreno-Navarrete, J.M., Escote, X., Ortega, F., et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 56 (2013), 2524–2537.
179. 179 Vreugdenhil, A.C., Dentener, M.A., Snoek, A.M., Greve, J.W., Buurman, W.A., Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 163 (1999), 2792–2798.
180. 180 Laugerette, F., Furet, J.P., Debard, C., et al. Oil composition of high-fat diet affects metabolic inflammation differently in connection with endotoxin receptors in mice. Am J Physiol Endocrinol Metab 302 (2012), E374–E386.
181. 181 Sun, L., Yu, Z., Ye, X., et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 33 (2010), 1925–1932.
182. 182 Elsing, C., Ernst, S., Kayali, N., Stremmel, W., Harenberg, S., Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy. Infection 39 (2011), 327–331.
183. 183 Schumann, R.R., Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 39 (2011), 989–993.
184. 184 Laugerette, F., Alligier, M., Bastard, J.P., et al. Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Mol Nutr Food Res 58 (2014), 1513–1518.
185. 185 Garcia de Guadiana-Romualdo, L., Espanol-Morales, I., Cerezuela-Fuentes, P., et al. Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Support Care Cancer 23 (2015), 2175–2182.
186. 186 Gonzalez-Quintela, A., Alonso, M., Campos, J., et al. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One, 8, 2013, e54600.
187. 187 Umoh, F.I., Kato, I., Ren, J., et al. Markers of systemic exposures to products of intestinal bacteria in a dietary intervention study. Eur J Nutr 55 (2016), 793–798.
188. 188 Lamping, N., Dettmer, R., Schroder, N.W., et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 101 (1998), 2065–2071.
189. 189 Vreugdenhil, A.C., Rousseau, C.H., Hartung, T., et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 170 (2003), 1399–1405.
190. 190 Moss, C.W., Daneshvar, M.I., Identification of some uncommon monounsaturated fatty acids of bacteria. J Clin Microbiol 30 (1992), 2511–2512.
191. 191 Wollenweber, H.W., Rietschel, E.T., Hofstad, T., Weintraub, A., Lindberg, A.A., Nature, type of linkage, quantity, and absolute configuration of (3-hydroxy) fatty acids in lipopolysaccharides from Bacteroides fragilis NCTC 9343 and related strains. J Bacteriol 144 (1980), 898–903.
192. 192 Brondz, I., Olsen, I., Haapasalo, M., Van Winkelhoff, A.J., Multivariate analyses of fatty acid data from whole-cell methanolysates of Prevotella, Bacteroides and Porphyromonas spp. J Gen Microbiol 137 (1991), 1445–1452.
193. 193 Leppanen, H.K., Taubel, M., Roponen, M., et al. Determinants, reproducibility, and seasonal variation of bacterial cell wall components and viable counts in house dust. Indoor Air 25 (2015), 260–272.
194. 194 Sonesson, A., Larsson, L., Schutz, A., Hagmar, L., Hallberg, T., Comparison of the limulus amebocyte lysate test and gas chromatography-mass spectrometry for measuring lipopolysaccharides (endotoxins) in airborne dust from poultry-processing industries. Appl Environ Microbiol 56 (1990), 1271–1278.
195. 195 Szponar, B., Krasnik, L., Hryniewiecki, T., Gamian, A., Larsson, L., Distribution of 3-hydroxy fatty acids in tissues after intraperitoneal injection of endotoxin. Clin Chem 49 (2003), 1149–1153.
196. 196 Binding, N., Jaschinski, S., Werlich, S., Bletz, S., Witting, U., Quantification of bacterial lipopolysaccharides (endotoxin) by GC-MS determination of 3-hydroxy fatty acids. J Environ Monit 6 (2004), 65–70.
197. 197 Huang, J.Y., Lee, S.M., Mazmanian, S.K., The human commensal Bacteroides fragilis binds intestinal mucin. Anaerobe 17 (2011), 137–141.
198. 198 Wu, S., Rhee, K.J., Albesiano, E., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 (2009), 1016–1022.
199. 199 Toprak, N.U., Yagci, A., Gulluoglu, B.M., et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 12 (2006), 782–786.
200. 200 Osipov, G.A., Verkhovtseva, N.V., Study of human microecology by mass spectrometry of microbial markers. Benef Microbes 2 (2011), 63–78.
201. 201 Szponar, B., Larsson, L., Domagala-Kulawik, J., Endotoxin markers in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Multidiscip Respir Med, 7, 2012, 54.
202. 202 Ferrando, R., Szponar, B., Sanchez, A., Larsson, L., Valero-Guillen, P.L., 3-Hydroxy fatty acids in saliva as diagnostic markers in chronic periodontitis. J Microbiol Methods 62 (2005), 285–291.
203. 203 Krasnik, L., Szponar, B., Walczak, M., Larsson, L., Gamian, A., Routine clinical laboratory tests correspond to increased serum levels of 3-hydroxy fatty acids, markers of endotoxins, in cardiosurgery patients. Arch Immunol Ther Exp (Warsz) 54 (2006), 55–60.
204. 204 Chen, Y.S., Lin, H.H., Liu, P.J., et al. Use of 3-hydroxy fatty acid concentrations in a murine air pouch infection model as a surrogate marker for LPS activity: a feasibility study using environmental Burkholderia cenocepacia isolates. J Microbiol Methods 87 (2011), 368–374.
205. 205 de Bont, N., Netea, M.G., Rovers, C., et al. LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment. J Interferon Cytokine Res 26 (2006), 101–107.
206. 206 Oku, H., Onotogi, M., Nagata, J., Wada, K., Chinen, I., Selective use of L-valine and L-isoleucine for the biosynthesis of branched-chain fatty acids in rat skin. Biosci Biotechnol Biochem 59 (1995), 891–895.
207. 207 Ran-Ressler, R.R., Bae, S., Lawrence, P., Wang, D.H., Brenna, J.T., Branched-chain fatty acid content of foods and estimated intake in the USA. Br J Nutr 112 (2014), 565–572.
208. 208 Lopez-Yglesias, A.H., Zhao, X., Quarles, E.K., et al. Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway. J Immunol 192 (2014), 1587–1596.
209. 209 Lodes, M.J., Cong, Y., Elson, C.O., et al. Bacterial flagellin is a dominant antigen in Crohns disease. J Clin Invest 113 (2004), 1296–1306.
210. 210 Ziegler, T.R., Luo, M., Estivariz, C.F., et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 294 (2008), R402–R410.
211. 211 Yang, B., Bostick, R.M., Tran, H.Q., et al. Circulating biomarkers of gut barrier function: correlates and nonresponse to calcium supplementation among colon adenoma patients. Cancer Epidemiol Biomarkers Prev 25 (2016), 318–326.
212. 212 Kong, S.Y., Tran, H.Q., Gewirtz, A.T., et al. Serum Endotoxins and Flagellin and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. Cancer Epidemiol Biomarkers Prev 25 (2016), 291–301.
213. 213 Kato, I., Boleij, A., Kortman, G.A., et al. Partial associations of dietary iron, smoking and intestinal bacteria with colorectal cancer risk. Nutr Cancer 65 (2013), 169–177.
214. 214 Yu, L.X., Yan, H.X., Liu, Q., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52 (2010), 1322–1333.
215. 215 Roderburg, C., Luedde, T., The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes 5 (2014), 441–445.
216. 216 Marks, M.A., Rabkin, C.S., Engels, E.A., et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 27 (2013), 469–474.